EUVIMEDEUVIMED entdecken
Crossref

Long-Term Longitudinal Analysis of Pulmonary Function before and after Biological Therapy in Severe Asthma

Wakana Uji, Toshiyuki Koya, Moe Tanaka, Yui Murai, Takahiro Matsuda, Shun Naramoto, Hiroshi Ueno, Ami Aoki, Kenjiro Shima, Yosuke Kimura, Takashi Hasegawa, Mayumi Sasagawa und 1 weitere

International Archives of Allergy and Immunology · 2025

DOI: 10.1159/000546394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Wakana Uji und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Therapy, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Biological agents are essential treatment options for severe asthma, particularly in cases with type 2 (T2) inflammation, due to their ability to improve symptoms, prevent exacerbations, and reduce the use of oral corticosteroids. However, limited data exist regarding their long-term effects on lung function, particularly on forced expiratory volume in 1 s (FEV1). This study aimed to analyze the longitudinal changes in FEV1 before and after the initiation of biological agents by following cases over an extended period.

Methods

This study included patients with at least three spirometric measurements before and after the initiation of biological agents, and a follow-up period of at least 2 years. The primary outcome was the annual change in FEV1 (ΔFEV1). Secondary outcomes included comparisons between patients with improved and deteriorated ΔFEV1, differences based on the type of biological agent used, and comparisons between patients who achieved clinical remission and those who did not.

Results

A total of 41 patients with severe asthma were analyzed. The overall ΔFEV1 significantly improved after the introduction of biological agents (p < 0.001). Patients with greater declines in FEV1 prior to treatment showed more pronounced improvements, especially among those treated with anti-IL-5 biologics (mepolizumab and benralizumab) or anti-IL-4 receptor antibodies (p = 0.016 and p = 0.026, respectively). Furthermore, patients with elevated T2 inflammation biomarkers, such as fractional exhaled nitric oxide and peripheral blood eosinophil count, exhibited greater improvements in FEV1.

Conclusion

This study indicates that biological agents may help prevent the progressive decline in lung function in severe asthma, particularly among patients with significantly declined lung function or elevated T2 inflammation biomarkers before treatment. Further research is needed to explore differences in efficacy across various biological agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsBiological TherapyLungHumansFemaleMaleMiddle AgedLongitudinal StudiesAdultForced Expiratory VolumeTreatment OutcomeRespiratory Function TestsSeverity of Illness IndexAntibodies, Monoclonal, HumanizedAged

Stichwörter der Autor:innen

Biological agentsClinical remissionLongitudinal changes in FEV1Severe asthmaT2 inflammation

Substanzen

Anti-Asthmatic AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, tkoya@med.niigata-u.ac.jp.
  • Department of General Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.
  • Gosen Central Hospital, Gosen, Japan.

Zitieren

APA

Uji, W., Koya, T., Tanaka, M., Murai, Y., Matsuda, T., Naramoto, S., Ueno, H., Aoki, A., Shima, K., Kimura, Y., Hasegawa, T., Sasagawa, M., & Kikuchi, T. (2025). Long-Term Longitudinal Analysis of Pulmonary Function before and after Biological Therapy in Severe Asthma. International Archives of Allergy and Immunology. https://doi.org/10.1159/000546394

Vancouver

Uji W, Koya T, Tanaka M, Murai Y, Matsuda T, Naramoto S, et al. Long-Term Longitudinal Analysis of Pulmonary Function before and after Biological Therapy in Severe Asthma. International Archives of Allergy and Immunology. 2025. doi:10.1159/000546394

BibTeX
@article{Uji2025,
  author = {Uji, Wakana and Koya, Toshiyuki and Tanaka, Moe and Murai, Yui and Matsuda, Takahiro and Naramoto, Shun and Ueno, Hiroshi and Aoki, Ami and Shima, Kenjiro and Kimura, Yosuke and Hasegawa, Takashi and Sasagawa, Mayumi and Kikuchi, Toshiaki},
  title = {Long-Term Longitudinal Analysis of Pulmonary Function before and after Biological Therapy in Severe Asthma},
  journal = {International Archives of Allergy and Immunology},
  year = {2025},
  doi = {10.1159/000546394}
}
Kostenlos starten →